Clear the hurdle of delayed methotrexate clearance due to acute kidney injury with VORAXAZE¹

Rapidly reduce toxic methotrexate levels with early administration* of VORAXAZE^2,3

≥97% Reduction in Plasma MTX Levels in 15 Minutes¹

*Within 48 to 60 hours of the start of the HDMTX infusion.³

REAL-WORLD EVIDENCE

Data supporting the use of VORAXAZE in patients experiencing HDMTX-induced AKI.

See the data

MTXPK.ORG TOOL

A tool designed to help clinicians understand the pharmacokinetics of HDMTX, especially regarding delayed clearance.^†

Get started

MATTHEW’S JOURNEY

Meet Matthew, an osteosarcoma survivor, and learn about his treatment journey.

Watch his story

STOCK VORAXAZE WITH CONFIDENCE

Replace expired product for free^‡

See replacement policy

^†

This tool is a reference aid and the information contained is not intended to be a substitute for the exercise of professional judgment.

^‡

Expired, unused product purchased through an authorized distributor of record may be eligible for replacement between 2 months before expiration and the end of the month after the product expires. Additional terms and conditions apply.

AKI, acute kidney injury; HDMTX, high-dose methotrexate; MTX, methotrexate.

Important Safety Information

Warnings and Precautions

Serious Hypersensitivity Reactions

Serious hypersensitivity reactions, including anaphylactic reactions, may occur. Serious hypersensitivity reactions occurred in less than 1% of patients

Monitoring Methotrexate Concentration/Interference With Assay

Methotrexate concentrations within 48 hours following Voraxaze^® administration can only be reliably measured by a chromatographic method due to interference from metabolites. Measurement of methotrexate concentrations within 48 hours of Voraxaze^® administration using immunoassays results in an overestimation of the methotrexate concentration

Adverse Reactions

In clinical trials, the most common related adverse events (occurring in >1% of patients) were paresthesia, flushing, nausea and/or vomiting, hypotension and headache

Drug Interactions

Voraxaze^® can decrease leucovorin concentration, which may decrease the effect of leucovorin rescue unless leucovorin is dosed as recommended, and may also reduce the concentrations of other folate analogs or folate analog metabolic inhibitors

Indication and limitations of use

Voraxaze^® is a carboxypeptidase indicated to reduce toxic plasma methotrexate concentration (greater than 1 micromole per liter) in adult and pediatric patients with delayed methotrexate clearance (plasma methotrexate concentrations greater than 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) due to impaired renal function
Limitations of Use: Voraxaze^® is not recommended for use in patients who exhibit the expected clearance and expected plasma methotrexate concentration. Reducing plasma methotrexate concentration in these patients may result in subtherapeutic exposure to methotrexate

Clear the hurdle of delayed methotrexate clearance due to acute kidney injury with VORAXAZE1